Active substance
Prevention and treatment of haemorrhage or surgical bleeding in adults (age 18 years and older) with von Willebrand disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or contraindicated. Veyvondi should not be used in the treatment of Haemophilia A.
| Product | Authorisation | Holder | Legal status |
|---|---|---|---|
| VEYVONDI 1300 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | PLGB 34078/0032 | BAXALTA INNOVATIONS GMBH | POM |
| VEYVONDI 650 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | PLGB 34078/0031 | BAXALTA INNOVATIONS GMBH | POM |
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), MHRA category lists of UK marketing authorisations (Open Government Licence v3.0), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.